Expanding knowledge, advancing understanding and applying scientific discoveries to enhance the health and lives of patients with diabetes is a hallmark of the Kovler Diabetes Center.

Building on a long history of seminal diabetes-related research at the University of Chicago, our affiliated principal investigators today work in a number of disciplines with implications for diabetes.

Researchers at Kovler and the University of Chicago enjoy the collaborative opportunities available across campus and beyond including our onsite Diabetes Research and Training Center, and with individual labs within the Section of Endocrinology, Diabetes & Metabolism. Basic scientists and clinical researchers as well as those looking for unique postdoctoral training will find unparalleled opportunities to pursue research at Kovler and the University of Chicago.

Clinical Research Opportunities

UChicago Medicine is participating in a phase 2 clinical trial, sponsored by Amgen, Inc. This study will assess the effectiveness, safety and tolerability of a potential new anti-obesity medication in adult participants with overweight or obesity, with or without Type 2 Diabetes Mellitus.

For more information about the study and to learn if you may be eligible, email Shanna Banogon, RN, call 773-702-7004 or visit https://www.clinicaltrials.gov/ct2/show/NCT05669599.

DESIGNATE is a phase 1b clinical trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). This study will assess the ability of the medication siplizumab to block or reduce t cells that attack the beta cells in the pancreas. We are currently seeking participants ages 18-45 with type one diabetes onset within 18 months. The principal investigator is Louis Philipson, MD, PhD. Contact Demetra Reyes at Demetra.Reyes@bsd.uchicago.edu or visit https://clinicaltrials.gov/ct2/show/NCT05574335 for more information.

UChicago Medicine is participating in a phase 3 clinical trial, sponsored by Dompé Farmaceutici S.p.A. This study will assess the effectiveness of the oral medication ladarixin in preserving b-cell function and delaying the progression of type one diabetes in adolescent and adult patients. We are currently seeking participants ages 14-45 with new-onset type one diabetes.

Contact Shanna Banogon, RN or visit https://clinicaltrials.gov/ct2/show/NCT04628481 for more information.

This study, Using Technology to Address Disparities and Promote Healthcare Equity in Type 1 Diabetes or EquiT1D, aims to address disparities in type 1 diabetes by helping adult patients with type 1 diabetes who have been hospitalized with diabetic ketoacidosis more than once in the last five years obtain continuous glucose monitors (CGMs). A patient navigator will then help the patient learn to use their CGM and contact them to follow up throughout the course of the study.

The EquiT1D research team led by Celeste Thomas, MD, MS, will evaluate this intervention’s impact on participants’ diabetes measurements and self-management practices. Its finding could create a new standard of care for diabetes management. Contact Elizabeth Murphy, MS, RDN, LDN for more information.

The University of Chicago is participating in the FOCUS study, sponsored by Novo-Nordisk. FOCUS is a 5-year long diabetic retinopathy outcomes trial. The goal is to establish the long-term effects of improved glycemic control when treated with once-weekly semaglutide on the development and progression of diabetic retinopathy in people with type 2 diabetes. The principal investigator for the study is center director Louis Philipson, MD, PhD, with Dimitra Skondra, MD, PhD serving as the principal ophthalmologist. Contact Triniece Pearson, PhD, MBA, RN, CCRC for more information.

The Multicenter Assessment of the Pancreas in Type 1 Diabetes (MAP-T1D) is an international team of researchers that focus on using magnetic resonance imaging (MRI) to investigate changes in pancreas volume and microarchitecture in individuals with diabetes. Center Director Louis Philipson, MD, PhD, and Siri Atma Greeley, MD, PhD, are the principal investigators at UChicago Medicine for the MAP-T1D project.

Contact Demetra Reyes or visit https://www.map-t1d.com/ for more information.

The Rare and Atypical Diabetes Network (RADIANT) trial, for which Center Director Louis Philipson, MD, PhD, and Siri Atma Greeley, MD, PhD, are the principal investigators, is discovering and defining rare and atypical forms of diabetes—a signature project of the Kovler Diabetes Center.

RADIANT is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). RADIANT is a network of universities, hospitals and clinics across the United States dedicated to better understanding atypical diabetes. Our team of academic institutions and scientists collaborate with physicians and healthcare groups to identify people with atypical diabetes and learn more about their health.

Contact Shanna Banogon, at shannad@medicine.bsd.uchicago.edu or visit https://www.atypicaldiabetesnetwork.org/ for more information.

UChicago Medicine is participating in a new clinical research study of an investigational infusion of islets in individuals who have been diagnosed with type 1 diabetes with low blood sugar and impaired hypoglycemic awareness. In this study, islets manufactured from stem cells are infused into the liver with a goal of providing replacement cells producing insulin for cells that have been lost.

Contact: Shanna Banagon, BSN, RN or Lindsay Basto, RN MSN for more information.

Diabetes Care at UChicago Medicine

Request an Appointment

The information you provide will enable us to assist you as efficiently as possible. A representative will contact you within one to two business days to help you schedule an appointment. 

To speak to someone directly, please call 1-888-824-0200. If you have symptoms of an urgent nature, please call your doctor or go to the emergency room immediately.


* Required Field

Diabetes Care